The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
Official Title: Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy
Study ID: NCT00207051
Brief Summary: This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Georgetn Univ Lombardi Can Ctr, Washington, District of Columbia, United States
University Of Miami Miller School Of Medicine, Miami, Florida, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Local Institution, Hamilton, Ontario, Canada
Local Institution, Toronto, Ontario, Canada
Local Institution, Amsterdam, , Netherlands
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR